SeaStar Medical Holding Corporation (ICU) Company Overview

What does SeaStar Medical Holding Corporation do?

SeaStar Medical Holding Corporation, traded on Nasdaq as ICU, is a commercial-stage medical-device company developing extracorporeal therapies for hyperinflammation in acute organ failure. Its Selective Cytopheretic Device, or SCD, is a disposable cartridge added to an existing continuous renal replacement therapy circuit. QUELIMMUNE is authorized for a narrow pediatric population with sepsis-related acute kidney injury. The FDA’s QUELIMMUNE page identifies it as a Humanitarian Device Exemption product based on safety and probable benefit, not demonstrated effectiveness.

One platform, one reportable segment

SeaStar reports one Device Segment, with all sales in the United States through March 31, 2026. The pediatric cartridge is the current business; adult acute kidney injury is the main scale opportunity. With no diversified portfolio, one clinical, procurement, supply, or financing setback can affect the whole company. The 2025 Form 10-K reports six Breakthrough Device Designations and 46 issued patents plus one pending application.

Pediatric commercialization shows hospitals can use and purchase the device; the adult pivotal program is both the scale engine and the largest clinical, regulatory, and financing dependency.

How does SeaStar Medical make money?

SeaStar sells single-use QUELIMMUNE cartridges to hospitals. The company’s official QUELIMMUNE materials describe sequential cartridges used within a CRRT treatment course. Revenue therefore depends on eligible cases, cartridges per patient, active hospitals, and realized price—not subscriptions or an installed software base.

Current revenue stream versus future revenue engine

Cumulative QUELIMMUNE revenue was about $1.9 million through March 31, 2026—evidence of paid use, but not enough to support the cost base. Adult approval could expand the patient pool and spread sales, quality, medical-affairs, and manufacturing costs across more procedures. Pediatric revenue is therefore commercialization validation, not mature-scale economics.

Why commercialization is hospital-by-hospital

Each account can require clinical training, value-analysis review, supply setup, and coordination across intensive-care teams. SeaStar moved from 10 active hospitals at year-end 2025 to 17 customers reported in May 2026, a 70% increase. Revenue still depends on eligible patients appearing at those sites and clinicians using the device consistently.

What does SeaStar Medical’s latest quarter show?

The Q1 2026 Form 10-Q shows improving commercial traction but early financial scale. Revenue rose 69% year over year to $495,000 and gross profit was $449,000, while $4.052 million of operating expenses produced a $3.603 million operating loss.

Revenue grew, but scale remains early

Gross margin is not yet mature economics

The 90.7% calculated gross margin is attractive but rests on only $495,000 of sales and may move with production, inventory, price, or case mix. The near-term test is whether gross profit can outgrow commercial and clinical infrastructure. The Q1 2026 earnings release linked hospital expansion with adult-trial progress.

How did SeaStar’s SCD platform reach commercial stage?

SeaStar’s history is a sequence of regulatory and commercial de-risking steps: public listing, pediatric authorization, direct sales, and expansion toward adult AKI. Each step reduced one uncertainty while exposing another.

1. 2007
   Corporate predecessor formed. The long development period reflects demanding scientific, regulatory, and manufacturing work.
2. 2022
   Public-company combination completed. Nasdaq access broadened financing options while adding listing and dilution risk.
3. 2022
   Adult AKI Breakthrough Device status and commercialization partnerships advanced. Adult AKI became the platform’s major expansion opportunity.
4. 2023
   NEUTRALIZE-AKI began enrolling. The adult study became the core clinical program and main R&D use.
5. February 2024
   FDA approved the pediatric HDE. This opened a narrow commercial pathway and tested hospital adoption.
6. July–August 2024
   First commercial shipment and direct-sales transition. SeaStar ended the Nuwellis arrangement and took direct control of customers.
7. 2025
   Commercial footprint and indication portfolio expanded. FY2025 revenue reached $1.234 million, with 10 active hospitals and six Breakthrough designations.
8. Q1–Q2 2026
   Customer count reached 17 and adult enrollment reached 198 of 339 subjects. Attention shifted to financing and completing the adult pathway.

What changed after direct commercialization?

Direct commercialization improved control over training, support, pricing, inventory, and feedback while shifting more execution cost to SeaStar. Ending the Nuwellis arrangement involved a $900,000 settlement. Growth from 10 active customers at year-end 2025 to 17 reported in May 2026 shows the direct model can add accounts; repeat case volume remains the harder test.

FDA pathways, hospital workflow, and the adult-AKI inflection point

QUELIMMUNE’s HDE covers patients weighing at least 10 kilograms and no more than 22 years old with sepsis-related AKI who require CRRT and receive antibiotics. The FDA HDE database records approval on February 21, 2024.

Why adult AKI is the pivotal program

NEUTRALIZE-AKI targets 339 subjects and a Day-90 composite endpoint of mortality or dialysis dependence. Enrollment reached 198 patients, or 58.4%, by May 13, 2026. SeaStar’s official pipeline also lists cardiorenal and hepatorenal programs, but adult AKI combines the largest stated opportunity with the most advanced development path.

Regulatory design creates both access and friction

The HDE enabled earlier access for a rare population but carries a narrow label and a lower evidentiary standard than standard premarket approval. Company materials cite 77% Day-60 survival and no dialysis among survivors in the pediatric study; the FDA states that effectiveness has not been demonstrated. Both facts belong in the analysis, and adult use requires a separate pathway.

What gives SeaStar Medical a competitive advantage?

SeaStar’s potential moat combines a differentiated immune-cell mechanism, CRRT integration, regulatory designations, clinical know-how, intellectual property, and early hospital relationships. These assets may be difficult to reproduce, but commercial scale and financial capacity remain weak.

Clinical, workflow, and intellectual-property assets

At year-end 2025, SeaStar reported 46 issued patents and one pending application: 21 issued patents and one application exclusively owned, plus 25 patents co-owned with the University of Michigan. The university license carries a 1% net-sales royalty. Key patent families generally run through 2031–2032, so terminal value cannot assume perpetual exclusivity. Six Breakthrough Device Designations support regulatory interaction but do not guarantee approval or reimbursement.

Where the moat is still incomplete

These analytical ratings highlight the core issue: SeaStar must convert its platform into approved indications, repeat utilization, reliable supply, and adequate financing. Fresenius Medical Care North America supplies the cartridge under an agreement through December 31, 2027, while SeaStar develops a second source. Supplier concentration therefore limits the moat.

How financially strong is SeaStar Medical?

At March 31, 2026, current assets were $10.764 million against $3.948 million of current liabilities, a calculated 2.7-times current ratio, and cash was $9.348 million. Despite that apparent liquidity, SeaStar said existing resources were insufficient for 12 months from the Q1 filing and disclosed substantial doubt about continuing as a going concern.

Cash runway and financing dependence

Q1 2026 operating cash outflow was $2.761 million. Dividing $9.348 million of cash by that burn gives about 3.4 quarters, or 10 months. This static calculation is not guidance and can change with working capital, trial timing, spending, and financing, but it explains why capital structure is part of the operating thesis.

Capital allocation is mainly R&D and operating survival

SeaStar had raised about $44.1 million under its shelf through March 31, 2026 and reported $55.9 million of gross capacity remaining, subject to “baby shelf” limits. About 2.700 million warrant share equivalents were outstanding versus 3.994 million common shares. Exercise is uncertain, but dilution scenarios are essential.

Who owns ICU stock, and how is SeaStar governed?

SeaStar has one common share class and no founder control. The 2026 proxy listed 3,993,719 shares at March 31, 2026. Intracoastal Capital held 398,973 beneficial shares, or 9.99%, while directors and officers as a group held 28,074, less than 1%. External shareholders and financing counterparties therefore matter more than insider voting control.

Control is dispersed, but dilution matters

Without a controlling holder, board independence, financing terms, votes, and equity incentives matter. In June 2026, shareholders increased the equity-plan reserve from 207,046 to 896,546 shares, adding 689,500. The annual-meeting Form 8-K reported 551,233 votes for, 223,813 against, 10,136 abstentions, and 1,395,732 broker non-votes.

Governance and incentives

The retention filing awarded $200,000 to the CEO and $140,000 to the CFO, vesting through March 2027. Retention protects execution during the pivotal trial, but stock-linked awards add dilution.

Opportunities, competition, and risks that can change the story

A small pediatric business sits beside a potentially transformative adult indication. Success could create rapid value; trial, FDA, supply, reimbursement, or funding setbacks could impair the company. The useful framework is a dependency map.

The opportunity set

The immediate opportunity is deeper use across 17 pediatric customers. Adult AKI is larger, followed by other inflammatory organ-failure indications. Platform reuse could spread scientific, quality, manufacturing, and commercial costs, but each indication still needs evidence and capital.

The risk map

Competition includes supportive care, CRRT alone, systemic immune therapies, other blood-purification devices, and future technologies. SeaStar must show enough incremental benefit to justify workflow and cost. Hospitals have strong buyer power, supplier concentration matters, and entry barriers come from evidence, patents, quality systems, and regulatory experience.

What should a DCF model and research brief monitor next?

A steady-state DCF is a poor starting point because SeaStar has negative free cash flow, a narrow current market, a pivotal binary program, and a changing capital structure. Use explicit pediatric-only, adult-approval, and delayed-development scenarios. Model revenue, gross margin, R&D, commercial infrastructure, financing, and diluted shares separately.

The metrics that connect operations to value

What is the key takeaway from SeaStar Medical analysis?

SeaStar has crossed a threshold many device developers do not: an FDA-authorized product is purchased by hospitals while the platform advances in a pivotal adult study. Evidence includes $1.234 million of FY2025 revenue, $495,000 in Q1 2026, 17 reported customers, six Breakthrough Device Designations, and 198 of 339 adult subjects enrolled by May 2026.

Differentiated science, CRRT integration, high early gross margin, expanding access, and a larger adult market support the story. Clinical delay, limited utilization, reimbursement friction, supplier concentration, finite patents, cash burn, listing risk, or dilution can weaken it. SeaStar is not a mature medtech compounder; clinical evidence, financing capacity, and per-share capital structure are inseparable.